Could an MS drug slow Alzheimer's brain shrinkage? new trial launches
NCT ID NCT06639282
First seen Mar 11, 2026 · Last updated Jun 16, 2026 · Updated 23 times
Summary
This study tests whether siponimod, a drug already used for multiple sclerosis, can safely slow brain shrinkage in people with mild Alzheimer's disease. About 105 participants will receive either the drug or a placebo for 12 months, then be monitored for another 6 months. The main goal is to check safety, while researchers also measure changes in brain volume, thinking skills, and disease-related markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Joseph's Hospital and Medical Center
RECRUITINGPhoenix, Arizona, 85013, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.